A small set of common blood biomarkers predicts which older adults will develop specific combinations of chronic diseases—and ...

Sarepta Therapeutics, Inc. , the leader in precision genetic medicine for rare diseases, today reports preliminary* fourth quarter and full-year 2025 net product revenues and cash, cash equivalents, ...

Researchers at Karolinska Institute analyzed blood samples from adults over 60 and identified seven biomarkers that predict ...

Mirum Pharmaceuticals, Inc. , a leading rare disease company, today provided its preliminary and unaudited estimates for full-year 2025 net product sales, year-end cash balance, corporate updates and ...

Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 monthsNotable ...

Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months Notable responses were ...

The data illustrate that several patients remained on zenocutuzumab well beyond progression, including multiple patients who continued treatment for more than one- or two-years post-progression.

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

We're only days away from the much-anticipated return of the "Gamma" Air Jordan 11. The style was originally introduced in 2013, and this month it's coming back to shelves as part of Jordan Brand's ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...